Founded in 2010, Althera is a Pharmaceutical R&D and commercialization organization. Our mission is to make significant positive impact on lives of patients by bringing to market innovative and complex products through our own development and in partnerships with other innovators.

Our Portfolio


Althera’s own development product AL-320 (rosuvastatin/ezetimibe tablets) is approved in 24 markets world-wide. AL-310 (atorvastatin/ezetimibe) product is in the final development stage and is expected to be filed in major markets shortly.

Additionally we have 14 more products in late stage pipeline in areas of Cardiovascular, Metabolic diseases, Infectious Diseases, CNS, and Oncology.

We also selectively license-in and acquire products to bring specialty products to market that make significant positive impact on the lives of patients we aim to serve.

We also undertake extensive licensing and acquisition activities to bring specialty products to market that make significant positive impact on the lives of patients we aim to serve.

Our Values


Althera instituted our values in 2010, the year Althera began its journey. These values have guided us since then and will guide our actions in the years to come. These values center around Patients, our commitment to Innovation, Excellence and Quality, and to Passion and People.